382 related articles for article (PubMed ID: 26093202)
1. ISCOMATRIX™ adjuvant promotes epitope spreading and antibody affinity maturation of influenza A H7N9 virus like particle vaccine that correlate with virus neutralization in humans.
Chung KY; Coyle EM; Jani D; King LR; Bhardwaj R; Fries L; Smith G; Glenn G; Golding H; Khurana S
Vaccine; 2015 Jul; 33(32):3953-62. PubMed ID: 26093202
[TBL] [Abstract][Full Text] [Related]
2. H5 N-terminal β sheet promotes oligomerization of H7-HA1 that induces better antibody affinity maturation and enhanced protection against H7N7 and H7N9 viruses compared to inactivated influenza vaccine.
Khurana S; Coyle EM; Verma S; King LR; Manischewitz J; Crevar CJ; Carter DM; Ross TM; Golding H
Vaccine; 2014 Nov; 32(48):6421-32. PubMed ID: 25284811
[TBL] [Abstract][Full Text] [Related]
3. Plant-derived H7 VLP vaccine elicits protective immune response against H7N9 influenza virus in mice and ferrets.
Pillet S; Racine T; Nfon C; Di Lenardo TZ; Babiuk S; Ward BJ; Kobinger GP; Landry N
Vaccine; 2015 Nov; 33(46):6282-9. PubMed ID: 26432915
[TBL] [Abstract][Full Text] [Related]
4. Recombinant virus-like particles elicit protective immunity against avian influenza A(H7N9) virus infection in ferrets.
Liu YV; Massare MJ; Pearce MB; Sun X; Belser JA; Maines TR; Creager HM; Glenn GM; Pushko P; Smith GE; Tumpey TM
Vaccine; 2015 Apr; 33(18):2152-8. PubMed ID: 25772674
[TBL] [Abstract][Full Text] [Related]
5. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus.
Khurana S; Chearwae W; Castellino F; Manischewitz J; King LR; Honorkiewicz A; Rock MT; Edwards KM; Del Giudice G; Rappuoli R; Golding H
Sci Transl Med; 2010 Jan; 2(15):15ra5. PubMed ID: 20371470
[TBL] [Abstract][Full Text] [Related]
6. Characterization of Humoral Responses Induced by an H7N9 Influenza Virus-Like Particle Vaccine in BALB/C Mice.
Zhang L; Lu J; Chen Y; Shi F; Yu H; Huang C; Cui L; Shi Z; Jiao Y; Hu Y
Viruses; 2015 Aug; 7(8):4369-84. PubMed ID: 26248076
[TBL] [Abstract][Full Text] [Related]
7. Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus.
Smith GE; Flyer DC; Raghunandan R; Liu Y; Wei Z; Wu Y; Kpamegan E; Courbron D; Fries LF; Glenn GM
Vaccine; 2013 Sep; 31(40):4305-13. PubMed ID: 23891795
[TBL] [Abstract][Full Text] [Related]
8. H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans.
Khurana S; Wu J; Verma N; Verma S; Raghunandan R; Manischewitz J; King LR; Kpamegan E; Pincus S; Smith G; Glenn G; Golding H
J Virol; 2011 Nov; 85(21):10945-54. PubMed ID: 21865396
[TBL] [Abstract][Full Text] [Related]
9. Recombinant influenza A virus hemagglutinin HA2 subunit protects mice against influenza A(H7N9) virus infection.
To KK; Zhang AJ; Chan AS; Li C; Cai JP; Lau CC; Li CG; Jahan AS; Wu WL; Li L; Tsang AK; Chan KH; Chen H; Yuen KY
Arch Virol; 2015 Mar; 160(3):777-86. PubMed ID: 25616843
[TBL] [Abstract][Full Text] [Related]
10. Heterologous prime-boost vaccination with MF59-adjuvanted H5 vaccines promotes antibody affinity maturation towards the hemagglutinin HA1 domain and broad H5N1 cross-clade neutralization.
Khurana S; Coyle EM; Dimitrova M; Castellino F; Nicholson K; Del Giudice G; Golding H
PLoS One; 2014; 9(4):e95496. PubMed ID: 24755693
[TBL] [Abstract][Full Text] [Related]
11. Antigenic Fingerprinting of Antibody Response in Humans following Exposure to Highly Pathogenic H7N7 Avian Influenza Virus: Evidence for Anti-PA-X Antibodies.
Khurana S; Chung KY; Coyle EM; Meijer A; Golding H
J Virol; 2016 Oct; 90(20):9383-93. PubMed ID: 27512055
[TBL] [Abstract][Full Text] [Related]
12. Serum IgG titres, but not avidity, correlates with neutralizing antibody response after H5N1 vaccination.
Pedersen GK; Höschler K; Øie Solbak SM; Bredholt G; Pathirana RD; Afsar A; Breakwell L; Nøstbakken JK; Raae AJ; Brokstad KA; Sjursen H; Zambon M; Cox RJ
Vaccine; 2014 Jul; 32(35):4550-4557. PubMed ID: 24950357
[TBL] [Abstract][Full Text] [Related]
13. Squalene-adjuvanted H7N9 virus vaccine induces robust humoral immune response against H7N9 and H7N7 viruses.
Wu CY; Chang CY; Ma HH; Wang CW; Chen YT; Hsiao PW; Chang CC; Chan CH; Liu CC; Chen JR
Vaccine; 2014 Jul; 32(35):4485-4494. PubMed ID: 24962757
[TBL] [Abstract][Full Text] [Related]
14. Influenza H7N9 LAH-HBc virus-like particle vaccine with adjuvant protects mice against homologous and heterologous influenza viruses.
Zheng D; Chen S; Qu D; Chen J; Wang F; Zhang R; Chen Z
Vaccine; 2016 Dec; 34(51):6464-6471. PubMed ID: 27866773
[TBL] [Abstract][Full Text] [Related]
15. Development of an Inactivated H7N9 Subtype Avian Influenza Serological DIVA Vaccine Using the Chimeric HA Epitope Approach.
Sun Z; Wang Q; Li G; Li J; Chen S; Qin T; Ma H; Peng D; Liu X
Microbiol Spectr; 2021 Oct; 9(2):e0068721. PubMed ID: 34585985
[TBL] [Abstract][Full Text] [Related]
16. Dual N-linked glycosylation at residues 133 and 158 in the hemagglutinin are essential for the efficacy of H7N9 avian influenza virus like particle vaccine in chickens and mice.
Wang Y; Li Q; Peng P; Zhang Q; Huang Y; Hu J; Hu Z; Liu X
Vet Microbiol; 2024 Jul; 294():110108. PubMed ID: 38729093
[TBL] [Abstract][Full Text] [Related]
17. Induction of neutralizing antibodies to influenza A virus H7N9 by inactivated whole virus in mice and nonhuman primates.
Pan W; Han L; Dong Z; Niu X; Li Z; Bao L; Li C; Luo Q; Yang Z; Li X; Huang J; Feng L; Qin C; Zhong N; Chen L
Antiviral Res; 2014 Jul; 107():1-5. PubMed ID: 24746458
[TBL] [Abstract][Full Text] [Related]
18. Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial.
Mulligan MJ; Bernstein DI; Winokur P; Rupp R; Anderson E; Rouphael N; Dickey M; Stapleton JT; Edupuganti S; Spearman P; Ince D; Noah DL; Hill H; Bellamy AR;
JAMA; 2014 Oct; 312(14):1409-19. PubMed ID: 25291577
[TBL] [Abstract][Full Text] [Related]
19. Optimal designs of an HA-based DNA vaccine against H7 subtype influenza viruses.
Zhang L; Jia N; Li J; Han Y; Cao W; Wang S; Huang Z; Lu S
Hum Vaccin Immunother; 2014; 10(7):1949-58. PubMed ID: 25424804
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of an 8 year interval heterologous prime-boost influenza A/H7N7-H7N9 vaccination.
El Sahly HM; Atmar RL; Patel SM; Bellamy A; Liu L; Hong W; Zhu H; Guan Y; Keitel WA;
Vaccine; 2019 May; 37(19):2561-2568. PubMed ID: 30955980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
